Development and External Validation of a Machine Learning-Based Model for Predicting Heart Failure Risk in Type 2 Diabetes

开发和外部验证基于机器学习的2型糖尿病心力衰竭风险预测模型

阅读:2

Abstract

BACKGROUND: Heart failure (HF) is a severe and common complication of type 2 diabetes mellitus (T2DM), associated with increased morbidity and mortality. Although the biomarker NT-proBNP, at a cut-off value of 125 pg/mL, has demonstrated satisfactory discriminatory power for predicting HF risk in T2DM patients, its measurement remains inaccessible in most primary healthcare settings in China. This study aimed to develop and externally validate a machine learning-based nomogram for predicting the risk of elevated NT-proBNP (≥125 pg/mL) as a surrogate for HF risk in patients with T2DM. METHODS: We retrospectively enrolled 564 T2DM patients as the development cohort and 302 from two external centers as the validation cohort. After feature selection via least absolute shrinkage and selection operator regression, five machine learning models were constructed and evaluated using 10-fold cross-validation. The optimal model was presented as a static nomogram and further deployed as an online web application for clinical use. RESULTS: Six key predictors were identified: estimated glomerular filtration rate, age, serum albumin, hemoglobin, urine albumin-to-creatinine ratio, and the binary indicator of age ≥ 65 years. Interpretability analysis using SHapley Additive exPlanations revealed estimated glomerular filtration rate as the most influential feature. The final machine learning-based nomogram achieved AUCs of 0.806 (95% CI: 0.767-0.845) in training and 0.861 (95% CI: 0.813-0.908) in external validation, with good calibration and clinical utility. Furthermore, the nomogram scores showed a significant positive correlation with established TRS-HF(DM) risk strata, supporting its clinical relevance. CONCLUSION: We developed and validated an interpretable machine learning-based nomogram that effectively predicts the risk of elevated NT-proBNP in T2DM patients using six routine clinical variables. This tool demonstrates robust performance and generalizability, offering a practical and accessible solution for HF risk stratification in resource-limited primary care settings in China.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。